drugset
drugset / Trial / NCT02759419

A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.

NCT02759419 ↗

Phase 4 Completed 18 enrolled Bayer
NaSingle-groupOpen-labelTreatment

Summary

To provide riociguat therapy to eligible patients with PAH originating from Bayer-sponsored trials with BAY63-2521/ Riociguat / Adempas® who are currently or recently treated in these trials until lack of patient benefit as assessed by investigator, or commercial availability and reimbursement.

Timeline

Start
2016-06-16
Primary completion
2025-09-15
Completion
2025-09-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Riociguat Other / unclassified 0.5 mg Oral
Subject Riociguat Other / unclassified 1 mg Oral
Subject Riociguat Other / unclassified 1.5 mg Oral
Subject Riociguat Other / unclassified 2 mg Oral
Subject Riociguat Other / unclassified 2.5 mg Oral

Indications

pulmonary arterial hypertension